Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more
Pluristem (PSTI) - Total Liabilities
Latest total liabilities as of March 2022: ILA38.98 Million ILA
Based on the latest financial reports, Pluristem (PSTI) has total liabilities worth ILA38.98 Million ILA as of March 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pluristem - Total Liabilities Trend (2014–2021)
This chart illustrates how Pluristem's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pluristem Competitors by Total Liabilities
The table below lists competitors of Pluristem ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Constellation Acquisition Corp I
OTCQB:CSTUF
|
USA | $22.03 Million |
|
Grayscale Digital Large Cap Fund Ll
OTCQX:GDLC
|
USA | $0.00 |
|
WEIR GROUP
BE:42W
|
Germany | €2.19 Billion |
|
Michichi Capital Corp.
V:MCCP-P
|
Canada | CA$497.00 |
|
Infinico Metals Corp.
V:INFM
|
Canada | CA$56.78K |
Liability Composition Analysis (2014–2021)
This chart breaks down Pluristem's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pluristem's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pluristem (2014–2021)
The table below shows the annual total liabilities of Pluristem from 2014 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-06-30 | ILA36.39 Million | +285.82% |
| 2020-06-30 | ILA9.43 Million | -0.61% |
| 2019-06-30 | ILA9.49 Million | -9.22% |
| 2018-06-30 | ILA10.45 Million | +43.53% |
| 2017-06-30 | ILA7.28 Million | -6.45% |
| 2016-06-30 | ILA7.79 Million | -22.24% |
| 2015-06-30 | ILA10.01 Million | -15.87% |
| 2014-06-30 | ILA11.90 Million | -- |